We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other oversold healthcare stocks.

The Promising Outlook for Healthcare Investments in 2024

Investing in healthcare stocks during lean economic times is generally regarded as defensive. This is because people typically do not cut back on their use of prescription medications or other essential healthcare services, even during difficult financial times. According to the Centers for Medicare and Medicaid Services (CMS), national healthcare spending is projected to reach an estimated $4.8 trillion in 2023 and grow at an annual rate of 5.6% between 2027 and 2032.

In the US, the healthcare sector is flourishing. According to a recent estimate, the country’s healthcare spending increased by 7.5% in 2023, above the nominal GDP growth rate for the same year. A record 93.1% of Americans now have health insurance, which helped fuel last year’s sharp increase in healthcare spending. The United States’ national healthcare spending is expected to increase at an average rate of 5.6% between 2023 and 2032, above the 4.3% growth predicted for GDP.

Additionally, the industry is growing quickly on a global scale. According to recent McKinsey projections, healthcare profits would increase at a compound annual growth rate (CAGR) of 7% from $583 billion in 2022 to over $800 billion by 2027. Although labor shortages and rising inflation rates continued to put pressure on the business in 2023, a good risk-reward climate in the sector is expected to make 2024 a year of recovery. According to the American investment firm, the events of 2023 have produced an alluring opportunity for investors to engage in the healthcare industry.

Investments in AI within the healthcare sector have grown rapidly, outpacing the tech industry, with $2.8 billion invested in AI healthcare corporations in 2024, and over $11 billion expected by the end of the year. According to a Silicon Valley Bank report, one-quarter of healthcare spending now goes to AI-driven companies. Deloitte’s 2024 Global Health Care Sector Outlook highlights high investor confidence, with $31.5 billion in private equity funding between 2019 and 2022. AI is expected to save $360 billion in U.S. healthcare over the next five years by improving patient care, diagnosis, treatment, and medical administration.

Optimism in the healthcare industry is growing as 2024 goes on. Financial experts anticipate better earnings this year despite 2023’s poor performance. The healthcare industry has a “favorable risk-reward environment,” according to BlackRock’s 2024 prediction, which also notes that investors now have an appealing starting point because of last year’s poor performance. In view of this, we will take a look at oversold stocks from the healthcare sector.

Our Methodology 

For our methodology, we used a stock screener and selected healthcare stocks that had an RSI below 30, mid-market cap, and high institutional ownership. Then we ranked the stocks based on their total number of hedge fund holders as of Insider Monkey’s database of Q3 2024.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Moderna, Inc. (NASDAQ:MRNA)

Number of Hedge Fund Holders: 34 

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines. It creates synthetic mRNA to instruct cells to produce proteins for preventing or treating various diseases, focusing on mRNA-based solutions for infectious diseases, immuno-oncology, rare diseases, and autoimmune disorders.

Moderna, Inc. (NASDAQ:MRNA) plans to file for approval of three new products this year: a new COVID/flu vaccine, a next-generation COVID-19 vaccine, and an RSV vaccine for adults aged 18-59. While the RSV vaccine rollout and positive EMA opinion boost investor confidence, the company also reports positive Phase III results for the flu/COVID-19 combo vaccine and partnerships with BARDA and Mitsubishi Tanabe Pharma. To save $1.1 billion annually by 2027, Moderna will discontinue five R&D programs and aims for operational breakeven by 2028, while continuing to advance clinical trials for mRNA-1647 and mRNA-3705.

In Q3 2024, Moderna, Inc. (NASDAQ:MRNA) reported an EPS of $0.03, and achieved a net income of $13 million, reversing a $3.6 billion loss in Q3 2023. The company’s revenue reached $1.9 billion, driven by strong COVID-19 vaccine sales following U.S. regulatory approval of its updated vaccine. The company reduced operating expenses by $500 million year-over-year through improved productivity and cost efficiencies in manufacturing, R&D, and SG&A. Additionally, the cost of sales dropped 77% to $514 million, reflecting strategic restructuring and lower inventory write-downs, enhancing profitability.

Baron Health Care Fund made the following comment about Moderna, Inc. (NASDAQ:MRNA) in its Q1 2023 investor letter:

“Moderna, Inc. (NASDAQ:MRNA) is a leader in the emerging field of mRNA-based vaccines and therapeutics and was one of the three main producers of the COVID-19 vaccine. Shares fell during the quarter. We believe as COVID shifts away from pandemic status and becomes an increasingly commercial market (rather than government-funded), there is increasing investor uncertainty around what a booster market could look like, which is pressuring shares. Looking beyond COVID, we think Moderna has the potential to disrupt the biopharmaceutical industry, from infectious disease vaccines to oncology, and we remain shareholders.”

Overall MRNA ranks 6th on our list of the oversold healthcare stocks to invest in. While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MRNA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.